BioTuesdays

Category - Markets

CytRx
Markets

HCW analyst assumes coverage of CytRx at buy; PT $4

H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of CytRx (NASDAQ:CYTR) with a “buy” rating and price target of $4. The stock was quoted at $1.91 in afternoon trading on April 7. CytRx’s two principal value...

May 7, 2018
Cannabis Wheaton Logo
Markets

Mackie Research starts Cannabis Wheaton at buy; PT $3

Mackie Research initiated coverage of Cannabis Wheaton with a “buy” rating and $3 price target. The stock closed at $1.56 on April 2. Analyst Greg McLeish writes that Wheaton’s “unique model is made up of three distinct...

May 3, 2018
Oryzon Genomics
Markets

Roth starts Oryzon Genomics at buy; PT €15

Roth Capital Partners initiated coverage of Oryzon Genomics (ISIN Code: ES0167733015, ORY) with a “buy” rating and price target of €15. The stock was recently quoted at €2.38. “In our view, the Spanish biotech Oryzon is...

May 1, 2018
Viking Therapeutics Logo
Markets

WB starts Viking Therapeutics at OP

William Blair launched coverage of Viking Therapeutics (NASDAQ:VKTX) with an “outperform” rating. The stock closed at $3.97 on April 27. Viking has a differentiated clinical pipeline focusing on modulating hormone...

April 30, 2018
Dova Pharmaceuticals
Markets

Ladenburg starts Dova Pharma at buy; PT $65

Ladenburg Thalmann initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “buy” rating and $65 price target. The stock was quoted at $26.55 near the close on April 26. Dova is focused on the development and...

April 26, 2018
Prothena
Markets

BTIG cuts Prothena to neutral; discontinues PT

BTIG downgraded Prothena (NASDAQ:PRTA) to “neutral” without a price target after the company discontinued development of NEOD001, an investigational antibody being evaluated to treat AL amyloidosis. The stock dropped...

April 24, 2018
Cipher Pharmaceuticals
Markets

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

Mackie Research Capital lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $5.30 from $7.10 after the company lowered first quarter expectations on the back of weak Absorica sales. Analyst Andre Uddin...

April 24, 2018
Homology Logo
Markets

BTIG starts Homology Medicines at buy; PT $35

BTIG initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $35 price target. The stock closed at $19.90 on April 23. Founded in 2015, Homology is a genetic medicine company that is focused on...

April 24, 2018
Matinas Biopharma
Markets

Maxim cuts Matinas BioPharma PT to $4 from $6

Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...

April 23, 2018